Abstract
Obesity has become a major concern among gastroenterologists due to its large influence on gastrointestinal and hepatic diseases: reflux esophagitis, pancreatitis, gallstone disease, liver fibrosis, and neoplastic tumors of the esophagus, pancreas, and colon. Studies of morbid obese subjects undergoing bariatric surgery have revealed that obesity is related with an increased prevalence of endoscopic and histologic gastritis. A recent study of health check-up subjects demonstrated an association of obesity with endoscopic gastritis and gastric ulcers. We recently investigated the underlying mechanisms of the effects of obesity on endoscopic gastritis in subjects undergoing health check-up examination, and demonstrated that adiponectin, a bioactive molecule released from visceral fat, could be a protective factor of endoscopic gastritis. We would like to propose a new category of gastritis, obesity-related gastritis, which could become dominant in the near future.
Journal Section:
Review
References
1.
Wisse BE, Kim F, Schwartz MW: Physiology. An integrative view of obesity. Science 2007;318:928–929.
[PubMed]
2.
Barak N, Ehrenpreis ED, Harrison JR, Sitrin MD: Gastro-oesophageal reflux disease in obesity: pathophysiological and therapeutic considerations. Obes Rev 2002;3:9–15.
[PubMed]
3.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M: Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569–578.
[PubMed]
4.
Delgado-Aros S, Locke GR 3rd, Camilleri M, Talley NJ, Fett S, Zinsmeister AR, Melton LJ 3rd: Obesity is associated with increased risk of gastrointestinal symptoms: a population-based study. Am J Gastroenterol 2004;99:1801–1806.
[PubMed]
5.
Talley NJ, Howell S, Poulton R: Obesity and chronic gastrointestinal tract symptoms in young adults: a birth cohort study. Am J Gastroenterol 2004;99:1807–1814.
[PubMed]
6.
Csendes A, Burgos AM, Smok G, Beltran M: Endoscopic and histologic findings of the foregut in 426 patients with morbid obesity. Obes Surg 2007;17:28–34.
[PubMed]
7.
Dutta SK, Arora M, Kireet A, Bashandy H, Gandsas A: Upper gastrointestinal symptoms and associated disorders in morbidly obese patients: a prospective study. Dig Dis Sci 2009;54:1243–1246.
[PubMed]
8.
Kim HJ, Yoo TW, Park DI, Park JH, Cho YK, Sohn CI, Jeon WK, Kim BI: Influence of overweight and obesity on upper endoscopic findings. J Gastroenterol Hepatol 2007;22:477–481.
[PubMed]
9.
Yamamoto S, Watabe K, Tsutsui S, Kiso S, Hamasaki T, Kato M, Kamada Y, Yoshida Y, Kihara S, Umeda M, Furubayashi A, Kinoshita K, Kishida O, Fujimoto T, Yamada A, Tsukamoto Y, Hayashi N, Matsuzawa Y: Lower serum level of adiponectin is associated with increased risk of endoscopic erosive gastritis. Dig Dis Sci 2011;56:2354–2360.
[PubMed]
10.
Matsuzawa Y: Adiponectin: a key player in obesity related disorders. Curr Pharm Des 2010;16:1896–1901.
[PubMed]
11.
Ouchi N, Walsh K: Adiponectin as an anti-inflammatory factor. Clin Chim Acta 2007;380:24–30.
[PubMed]
12.
Yamada T, Araki H, Watabe K, Kamada Y, Kiso S, Ogiyama H, Nishihara T, Kihara S, Funahashi T, Shimomura I, Tsutsui S, Hayashi N: Adiponectin deficiency enhanced the severity of cerulein-induced chronic pancreatitis in mice. J Gastroenterol 2010;45:742–749.
[PubMed]
13.
Ogiyama H, Kamada Y, Kiso S, Araki H, Yamada T, Nishihara T, Watabe K, Tochino Y, Kihara S, Funahashi T, Kanno K, Shimomura I, Tsutsui S, Tazuma S, Hayashi N: Lack of adiponectin promotes formation of cholesterol gallstones in mice. Biochem Biophys Res Commun 2010;399:352–358.
[PubMed]
14.
Rothenbacher D, Brenner H: Burden of Helicobacter pylori and H. pylori-related diseases in developed countries: recent developments and future implications. Microbes Infect 2003;5:693–703.
[PubMed]
15.
Haruma K, Okamoto S, Kawaguchi H, Gotoh T, Kamada T, Yoshihara M, Sumii K, Kajiyama G: Reduced incidence of Helicobacter pylori infection in young Japanese persons between the 1970s and the 1990s. J Clin Gastroenterol 1997;25:583–586.
[PubMed]
16.
World Health Organization. Available at https://apps.who.int/infobase/ (accessed May 12, 2011).
© 2012 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2012
You do not currently have access to this content.
